跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Aclipak Concentrate for Solution for Infusion 6mg/ ml - HSA Drug Approval Details
Approvals
/
HSA
/
Aclipak Concentrate for Solution for Infusion 6mg/ ml
Approved
THERAPEUTIC
Aclipak Concentrate for Solution for Infusion 6mg/ ml
S.C. Sindan - Pharma S.R.L
🇸🇬 Health Sciences Authority
Approval Date
Jan 19, 2010
Approval ID
10d756267243a933
Company
S.C. Sindan - Pharma S.R.L
Type
Therapeutic
Approval Details
Approval Id
10d756267243a933
Drug Name
Aclipak Concentrate for Solution for Infusion 6mg/ ml
Product Name
Aclipak Concentrate for Solution for Infusion 6mg/ ml
Approval Number
SIN13752P
Approval Date
2010-01-19
Registrant
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence Holder
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INFUSION, SOLUTION CONCENTRATE
Route Of Administration
INTRAVENOUS
Atc Code
L01CD01
Atc Item Name
paclitaxel
Pharma Manufacturer Name
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Company Detail Path
/organization/teva-pharmaceutical-investments-singapore-pte-ltd
Active Ingredients
Paclitaxel
6.00 mg
Paclitaxel
6.00 mg
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Jan 19, 2010
Approval ID
10d756267243a933
Type
Therapeutic
Back to HSA Approvals
